title: An approach to analyse the specific impact of rapamycin on mRNA-ribosome association.
abstract: BACKGROUND
  Recent work, using both cell culture model systems and tumour derived cell lines, suggests that the differential recruitment into polysomes of mRNA populations may be sufficient to initiate and maintain tumour formation. Consequently, a major effort is underway to use high density microarray profiles to establish molecular fingerprints for cells exposed to defined drug regimes. The aim of these pharmacogenomic approaches is to provide new information on how drugs can impact on the translational read-out within a defined cellular background.
  
  
  METHODS
  We describe an approach that permits the analysis of de-novo mRNA-ribosome association in-vivo during short drug exposures. It combines hypertonic shock, polysome fractionation and high-throughput analysis to provide a molecular phenotype of translationally responsive transcripts. Compared to previous translational profiling studies, the procedure offers increased specificity due to the elimination of the drugs secondary effects (e.g. on the transcriptional read-out). For this pilot "proof-of-principle" assay we selected the drug rapamycin because of its extensively studied impact on translation initiation.
  
  
  RESULTS
  High throughput analysis on both the light and heavy polysomal fractions has identified mRNAs whose re-recruitment onto free ribosomes responded to short exposure to the drug rapamycin. The results of the microarray have been confirmed using real-time RT-PCR. The selective down-regulation of TOP transcripts is also consistent with previous translational profiling studies using this drug.
  
  
  CONCLUSIONS
  The technical advance outlined in this manuscript offers the possibility of new insights into mRNA features that impact on translation initiation and provides a molecular fingerprint for transcript-ribosome association in any cell type and in the presence of a range of drugs of interest. Such molecular phenotypes defined pre-clinically may ultimately impact on the evaluation of a particular drug in a living cell.
authors.affiliation: Department of Microbiology and Molecular Medicine, University of Geneva Medical School (CMU), 1 rue Michel Servet, CH-1211 Geneva, Switzerland. Raphael.Genolet@medecine.unige.ch
authors.forename: Raphael
authors.initials: R
authors.lastname: Genolet
authors.forename: Tanguy
authors.initials: T
authors.lastname: Araud
authors.forename: Laetitia
authors.initials: L
authors.lastname: Maillard
authors.forename: Pascale
authors.initials: P
authors.lastname: Jaquier-Gubler
authors.forename: Joseph
authors.initials: J
authors.lastname: Curran